These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 25894292)
41. Oxidative imbalance in child and adolescent patients with attention-deficit/hyperactivity disorder. Ceylan M; Sener S; Bayraktar AC; Kavutcu M Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1491-4. PubMed ID: 20732373 [TBL] [Abstract][Full Text] [Related]
42. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. Faraone SV; Glatt SJ J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220 [TBL] [Abstract][Full Text] [Related]
43. Role of Oxidative Stress and Neuroinflammation in Attention-Deficit/Hyperactivity Disorder. Corona JC Antioxidants (Basel); 2020 Oct; 9(11):. PubMed ID: 33114154 [TBL] [Abstract][Full Text] [Related]
44. The dopaminergic hypothesis of attention-deficit/hyperactivity disorder needs re-examining. Gonon F Trends Neurosci; 2009 Jan; 32(1):2-8. PubMed ID: 18986716 [TBL] [Abstract][Full Text] [Related]
45. Physiological and psychological stress responses in adults with attention-deficit/hyperactivity disorder (ADHD). Lackschewitz H; Hüther G; Kröner-Herwig B Psychoneuroendocrinology; 2008 Jun; 33(5):612-24. PubMed ID: 18329819 [TBL] [Abstract][Full Text] [Related]
46. The control of responsiveness in ADHD by catecholamines: evidence for dopaminergic, noradrenergic and interactive roles. Oades RD; Sadile AG; Sagvolden T; Viggiano D; Zuddas A; Devoto P; Aase H; Johansen EB; Ruocco LA; Russell VA Dev Sci; 2005 Mar; 8(2):122-31. PubMed ID: 15720370 [TBL] [Abstract][Full Text] [Related]
47. Attention-deficit hyperactivity disorder (ADHD): an updated review of the essential facts. Tarver J; Daley D; Sayal K Child Care Health Dev; 2014 Nov; 40(6):762-74. PubMed ID: 24725022 [TBL] [Abstract][Full Text] [Related]
48. Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder. Hariri M; Djazayery A; Djalali M; Saedisomeolia A; Rahimi A; Abdolahian E Malays J Nutr; 2012 Dec; 18(3):329-35. PubMed ID: 24568073 [TBL] [Abstract][Full Text] [Related]
49. Lipid profile, fatty acid composition and pro- and anti-oxidant status in pediatric patients with attention-deficit/hyperactivity disorder. Spahis S; Vanasse M; Bélanger SA; Ghadirian P; Grenier E; Levy E Prostaglandins Leukot Essent Fatty Acids; 2008; 79(1-2):47-53. PubMed ID: 18757191 [TBL] [Abstract][Full Text] [Related]
50. Increased cerebral perfusion in adult attention deficit hyperactivity disorder is normalised by stimulant treatment: a non-invasive MRI pilot study. O'Gorman RL; Mehta MA; Asherson P; Zelaya FO; Brookes KJ; Toone BK; Alsop DC; Williams SC Neuroimage; 2008 Aug; 42(1):36-41. PubMed ID: 18511306 [TBL] [Abstract][Full Text] [Related]
51. Targeting the dopamine system in the treatment of attention-deficit/hyperactivity disorder. Staller JA; Faraone SV Expert Rev Neurother; 2007 Apr; 7(4):351-62. PubMed ID: 17425490 [TBL] [Abstract][Full Text] [Related]
52. Oxidative & nitrosative stress in depression: why so much stress? Moylan S; Berk M; Dean OM; Samuni Y; Williams LJ; O'Neil A; Hayley AC; Pasco JA; Anderson G; Jacka FN; Maes M Neurosci Biobehav Rev; 2014 Sep; 45():46-62. PubMed ID: 24858007 [TBL] [Abstract][Full Text] [Related]
53. Treatment of attention-deficit/hyperactivity disorder. Jadad AR; Boyle M; Cunningham C; Kim M; Schachar R Evid Rep Technol Assess (Summ); 1999 Nov; (11):i-viii, 1-341. PubMed ID: 10790990 [TBL] [Abstract][Full Text] [Related]
54. Attention deficit hyperactivity disorder in the European adult population: prevalence, disease awareness, and treatment guidelines. Ramos-Quiroga JA; Montoya A; Kutzelnigg A; Deberdt W; Sobanski E Curr Med Res Opin; 2013 Sep; 29(9):1093-104. PubMed ID: 23742051 [TBL] [Abstract][Full Text] [Related]
55. Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder? Potter AS; Newhouse PA; Bucci DJ Behav Brain Res; 2006 Dec; 175(2):201-11. PubMed ID: 17081628 [TBL] [Abstract][Full Text] [Related]
56. Oxidative stress in children with attention deficit hyperactivity disorder. Oztop D; Altun H; Baskol G; Ozsoy S Clin Biochem; 2012 Jul; 45(10-11):745-8. PubMed ID: 22497926 [TBL] [Abstract][Full Text] [Related]
57. Changes in oxidative stress and cellular immunity serum markers in attention-deficit/hyperactivity disorder. Ceylan MF; Sener S; Bayraktar AC; Kavutcu M Psychiatry Clin Neurosci; 2012 Apr; 66(3):220-6. PubMed ID: 22443244 [TBL] [Abstract][Full Text] [Related]
58. Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder. van der Kooij MA; Glennon JC Neurosci Biobehav Rev; 2007; 31(4):597-618. PubMed ID: 17316796 [TBL] [Abstract][Full Text] [Related]
59. Oxidative stress and immune aberrancies in attention-deficit/hyperactivity disorder (ADHD): a case-control comparison. Verlaet AAJ; Breynaert A; Ceulemans B; De Bruyne T; Fransen E; Pieters L; Savelkoul HFJ; Hermans N Eur Child Adolesc Psychiatry; 2019 May; 28(5):719-729. PubMed ID: 30350094 [TBL] [Abstract][Full Text] [Related]
60. [Atomoxetine safety and efficacy in children with attention deficit/hyperactivity disorder (ADHD): initial phase of 10-week treatment in a relapse prevention study with a Spanish sample]. Escobar R; Soutullo C; San Sebastián J; Fernández E; Julián I; Lahortiga F Actas Esp Psiquiatr; 2005; 33(1):26-32. PubMed ID: 15704028 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]